**Research Article [specific categories include: Small Molecule Therapeutics; Large Molecule Therapeutics; Cancer Biology and Signal Transduction; Companion Diagnostics and Cancer Biomarkers; Models and Technologies]**

**Title** [insert FULL TITLE here; no abbreviations]

[full NAMES (including first and middle names or initials) and AFFILIATIONS of all authors; no academic degrees]

**Running title:** [60 characters (including spaces) or less]

**Keywords:** [insert five descriptive keywords here]

**Financial support:** [including source and number of grants]

**Corresponding author:** [name, postal address, telephone and fax numbers, and email address]

**Conflicts of interest:** [insert any conflicts of interest here; otherwise ‘The authors declare no conflicts of interest]

**Word count:** [insert WORD COUNT here (excluding references); maximum 5000 words of text (exclusive of references)]

**Total number of figures and tables:** [insert here; maximum 6 tables and/or figures]

**Abstract**

[insert ABSTRACT here; maximum 250 words; no references and minimal use of abbreviations]

**Introduction**

[insert TEXT here; a good introduction will be about one page of text, clearly state the problem, introduce relevant literature, note any controversies, and present the aim or hypothesis in the last paragraph; example reference format using Endnote: (1, 2)]

**Materials and Methods**

[reference original texts when using established methods]

**Results**

[insert here; do not combine with DISCUSSION]

**Discussion**

[insert DISCUSSION here, must not be redundant with results section, highlight main conclusions in final paragraph]

**Acknowledgments**

[others who contributed to the work but are not listed as authors; seek written permission for those included here]

**References**

[maximum 50 references; we recommend using citation management software, such as Endnote; for an excellent free alternative see [Mendeley](http://www.mendeley.com/)]

1. Paulson AK, Linklater ES, Berghuis BD, App CA, Oostendorp LD, Paulson JE, et al. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Molecular cancer research : MCR. 2013;11:1112-21.

2. Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. Molecular cancer therapeutics. 2013;12:1665-75.

**Tables**

[each on separate page, portrait, one-line title in bold, symbols and abbreviations immediately below the table with lower-case alphabetical letters; each table must have a descriptive title; include appropriate statistical analyses within tables]

**Figure Legends**

**Figure x.** [listed one after another; do not add legend to figure files; do not embed figures in this file; present each figure with a short summary of abut 15 words followed by a more comprehensive description]

[Did you find this template useful? To find out more about how Nextgenediting can help you publish visit <http://www.nextgenediting.com>. Connect with us via social media ([LinkedIn](http://www.linkedin.com/company/nextgenediting/), [Facebook](https://www.facebook.com/pages/Nextgenediting/131606863661962), or [Twitter](https://twitter.com/nextgenediting)) for news and special offers!]